Ipsos Rolls Out MDx Portfolio in Japan and Australia

Ipsos Healthcare has extended its Molecular Diagnostics (MDx) portfolio to Japan and Australia, where it will initially focus on oncology, with other therapy areas to be rolled out in the coming months.

The MDx Monitor has been running in the USA since 2012 and launched in the EU last year. The service gathers input from a wide range of stakeholders, and combines patient and test-level data with perceptual data to enable subscribers to understand the decision-making process; the impact of testing drug shares; and the uptake of new methodologies for reimbursement and payer restriction.

The new Japanese Oncology MDx Monitor covers the MDx market in breast cancer, gastric cancer and lung cancer, gathering data from 160 physicians; while the Australian equivalent covers the MDx market in lung cancer and melanoma, with data collected from a mix of oncologists and pathologists.

Pieter De Richter (pictured), who heads up the division's Molecular Diagnostics Monitors, said: 'Japan and Australia have unique differences that set them aside from the US and EU5, and being able to fully understand the complexities of molecular testing at a country-specific level will be of great benefit to companies looking to expand or fine-tune their MDx/CDx strategies in either of these important global markets.'

Web site: www.ipsos.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Ipsos UK
• All news
• MrWeb info